Engana

enGene is a clinical-stage biotechnology company focused on mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company utilizes its proprietary Dually Derivatized Oligochitosan (DDX) platform, a non-viral delivery system designed to transport genetic payloads directly to target tissues with high potency and low toxicity. Its lead program, detalimogene voraplasmid (EG-70), is currently in a pivotal Phase 2 clinical trial (LEGEND) for the treatment of patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). By focusing on localized delivery, enGene aims to address significant unmet clinical needs in oncology and other therapeutic areas while avoiding the systemic side effects often associated with traditional therapies.